Literature DB >> 34491555

Adverse Events in the Digital Age: Finding the Sharpest Tool in the Box.

Robert Di Giovanni1, Andrew Cochrane2, David J Lewis3,4.   

Abstract

Digital health arrived to society and it generates data which is growing exponentially. Pharma and medical device industry recently embarked on this journey. Digital tools became everyday experience both in development as well as post-market settings. These non-traditional data sources may contain relevant safety, efficacy, effectiveness and other knowledge, which are valuable for understanding and further characterizing safety profile of a given medicinal and medical device product. It is however unclear what new responsibilities are associated with the use of such tools and data generated / collected by them. Current regulatory framework does not provide very clear guidance on it. Teams are struggling to interpret expectations originated from regulations, ethics and patients. We present practical approaches for data management and we suggest that a detailed assessment of projects is conducted to identify obligations for screening digitally-sourced data. Compliance with regulations is obligatory, but it is also incumbent on the sponsor to define a data management strategy covering the purpose of the activities, and the value of the data gathered. Decisions thereafter should be aligned with the mission, vision, and objectives defined by the sponsor.
© 2021. The Drug Information Association, Inc.

Entities:  

Keywords:  Automation; Digital data; Pharmacovigilance; Technology; Typology

Year:  2021        PMID: 34491555     DOI: 10.1007/s43441-021-00337-1

Source DB:  PubMed          Journal:  Ther Innov Regul Sci        ISSN: 2168-4790            Impact factor:   1.778


  1 in total

1.  Updating of a method for causality assessment of adverse drug reactions.

Authors:  J Venulet; A G Ciucci; G C Berneker
Journal:  Int J Clin Pharmacol Ther Toxicol       Date:  1986-10
  1 in total
  1 in total

Review 1.  Advancing drug safety science by integrating molecular knowledge with post-marketing adverse event reports.

Authors:  Theodoros G Soldatos; Sarah Kim; Stephan Schmidt; Lawrence J Lesko; David B Jackson
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2022-02-20
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.